M
MaxCyte Inc
LSE:MXCT
MaxCyte Inc
LSE:MXCT
Price:
0.7496
GBX
-0.96%
Market Closed
Market Cap:
£83.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
MaxCyte Inc
LSE:MXCT
|
US |
Balance Sheet
Balance Sheet Decomposition
MaxCyte Inc
MaxCyte Inc
Balance Sheet Decomposition is not available for
MaxCyte Inc
MaxCyte Inc
Balance Sheet
MaxCyte Inc
MaxCyte Inc
Currency: USD
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
1
|
1
|
3
|
2
|
12
|
25
|
11
|
15
|
19
|
48
|
11
|
47
|
28
|
20
|
|
| Cash Equivalents |
1
|
1
|
3
|
2
|
12
|
25
|
11
|
15
|
19
|
48
|
11
|
47
|
28
|
20
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
16
|
207
|
216
|
122
|
127
|
83
|
|
| Total Receivables |
1
|
1
|
1
|
2
|
2
|
3
|
5
|
3
|
5
|
7
|
14
|
6
|
5
|
4
|
|
| Accounts Receivables |
1
|
1
|
1
|
2
|
2
|
3
|
5
|
3
|
5
|
7
|
14
|
6
|
5
|
4
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
4
|
5
|
9
|
12
|
9
|
8
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
3
|
3
|
8
|
4
|
4
|
|
| Total Current Assets |
3
|
2
|
6
|
6
|
16
|
31
|
23
|
25
|
45
|
270
|
252
|
190
|
172
|
118
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
6
|
7
|
13
|
34
|
35
|
30
|
28
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
6
|
7
|
13
|
34
|
35
|
30
|
28
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
4
|
6
|
10
|
14
|
17
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
43
|
36
|
53
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
2
|
|
| Total Assets |
3
N/A
|
3
-11%
|
6
+152%
|
6
+2%
|
16
+152%
|
31
+95%
|
24
-23%
|
30
+23%
|
52
+73%
|
284
+448%
|
287
+1%
|
268
-6%
|
239
-11%
|
203
-15%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
2
|
3
|
4
|
4
|
2
|
1
|
2
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
6
|
7
|
8
|
12
|
9
|
9
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
1
|
2
|
3
|
2
|
2
|
3
|
5
|
7
|
7
|
5
|
5
|
4
|
|
| Total Current Liabilities |
3
|
4
|
4
|
5
|
6
|
6
|
7
|
9
|
12
|
16
|
15
|
18
|
16
|
14
|
|
| Long-Term Debt |
0
|
0
|
4
|
4
|
5
|
5
|
5
|
5
|
5
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
6
|
17
|
18
|
17
|
17
|
|
| Total Liabilities |
3
N/A
|
4
+18%
|
8
+98%
|
10
+20%
|
11
+16%
|
12
+7%
|
12
+2%
|
16
+37%
|
19
+13%
|
21
+14%
|
33
+54%
|
36
+10%
|
33
-8%
|
31
-7%
|
|
| Equity | |||||||||||||||
| Common Stock |
31
|
32
|
44
|
45
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
31
|
34
|
45
|
48
|
52
|
62
|
71
|
83
|
95
|
114
|
138
|
176
|
217
|
261
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
56
|
81
|
82
|
96
|
128
|
376
|
391
|
407
|
422
|
432
|
|
| Total Equity |
1
N/A
|
2
-150%
|
2
-7%
|
3
-94%
|
5
N/A
|
20
+284%
|
12
-37%
|
14
+11%
|
33
+144%
|
263
+692%
|
254
-3%
|
232
-9%
|
206
-11%
|
171
-17%
|
|
| Total Liabilities & Equity |
3
N/A
|
3
-11%
|
6
+152%
|
6
+2%
|
16
+152%
|
31
+95%
|
24
-23%
|
30
+23%
|
52
+73%
|
284
+448%
|
287
+1%
|
268
-6%
|
239
-11%
|
203
-15%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
44
|
44
|
44
|
44
|
44
|
51
|
51
|
57
|
77
|
101
|
102
|
104
|
106
|
107
|
|
Switch to:
Switch to:
See Also
Discover More
